Resmed Inc (NYSE: RMD) has experienced a rise in its stock price by 0.17 compared to its previous closing price of 214.08. However, the company has seen a gain of 0.22% in its stock price over the last five trading days. seekingalpha.com reported 2025-04-23 that ResMed Inc. (NYSE:RMD ) Q3 2025 Earnings Conference Call April 23, 2025 4:30 PM ET Company Participants Mick Farrell – Chairman & Chief Executive Officer Salli Schwartz – Chief Investor Relations Officer Brett Sandercock – Chief Financial Officer Conference Call Participants Lyanne Harrison – Bank of America Margaret Kaczor – William Blair Davin Thillainathan – Goldman Sachs Anthony Petrone – Mizuho Group David Low – JPMorgan Saul Hadassin – Barrenjoey Dan Hurren – MST Matt Taylor – Jefferies Steve Wheen – Jarden David Bailey – Morgan Stanley Brett Fishbin – KeyBanc Capital Markets Operator Greetings, and welcome to the Q3 Fiscal Year 2025 ResMed Earnings Conference Call. My name is Kevin, and I’ll be your operator for today’s call.
Is It Worth Investing in Resmed Inc (NYSE: RMD) Right Now?
Resmed Inc (NYSE: RMD) has a price-to-earnings ratio of 25.33x that is above its average ratio. Additionally, the 36-month beta value for RMD is 0.79. There are mixed opinions on the stock, with 8 analysts rating it as a “buy,” 4 rating it as “overweight,” 6 rating it as “hold,” and 1 rating it as “sell.”
The public float for RMD is 145.81M and currently, short sellers hold a 6.10% ratio of that float. The average trading volume of RMD on April 24, 2025 was 1.11M shares.
RMD’s Market Performance
The stock of Resmed Inc (RMD) has seen a 0.22% increase in the past week, with a -3.80% drop in the past month, and a -13.30% fall in the past quarter. The volatility ratio for the week is 3.53%, and the volatility levels for the past 30 days are at 3.70% for RMD. The simple moving average for the last 20 days is -0.33% for RMD’s stock, with a simple moving average of -7.51% for the last 200 days.
Analysts’ Opinion of RMD
Many brokerage firms have already submitted their reports for RMD stocks, with Morgan Stanley repeating the rating for RMD by listing it as a “Overweight.” The predicted price for RMD in the upcoming period, according to Morgan Stanley is $280 based on the research report published on March 19, 2025 of the current year 2025.
RMD Trading at -4.00% from the 50-Day Moving Average
After a stumble in the market that brought RMD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -18.48% of loss for the given period.
Volatility was left at 3.70%, however, over the last 30 days, the volatility rate increased by 3.53%, as shares sank -3.10% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -10.11% lower at present.
During the last 5 trading sessions, RMD rose by +0.22%, which changed the moving average for the period of 200-days by +10.12% in comparison to the 20-day moving average, which settled at $215.15. In addition, Resmed Inc saw -6.23% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RMD starting from Sandercock Brett, who sale 1,000 shares at the price of $215.58 back on Apr 08 ’25. After this action, Sandercock Brett now owns 89,864 shares of Resmed Inc, valued at $215,580 using the latest closing price.
Farrell Michael J., the Chief Executive Officer of Resmed Inc, sale 8,009 shares at $209.85 during a trade that took place back on Apr 07 ’25, which means that Farrell Michael J. is holding 455,472 shares at $1,680,699 based on the most recent closing price.
Stock Fundamentals for RMD
Current profitability levels for the company are sitting at:
- 0.32 for the present operating margin
- 0.59 for the gross margin
The net margin for Resmed Inc stands at 0.26. The total capital return value is set at 0.24. Equity return is now at value 25.65, with 17.78 for asset returns.
Based on Resmed Inc (RMD), the company’s capital structure generated 0.13 points at debt to capital in total, while cash flow to debt ratio is standing at 1.97. The debt to equity ratio resting at 0.15. The interest coverage ratio of the stock is 203.88.
Currently, EBITDA for the company is 1.53 billion with net debt to EBITDA at -0.06. When we switch over and look at the enterprise to sales, we see a ratio of 6.25. The receivables turnover for the company is 5.53for trailing twelve months and the total asset turnover is 0.66. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.33.
Conclusion
In conclusion, Resmed Inc (RMD) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
